57 related articles for article (PubMed ID: 19905879)
1. Comparative efficacy and acceptability of pharmacotherapeutic agents for anxiety disorders in children and adolescents: a mixed treatment comparison meta-analysis.
Uthman OA; Abdulmalik J
Curr Med Res Opin; 2010 Jan; 26(1):53-9. PubMed ID: 19905879
[TBL] [Abstract][Full Text] [Related]
2. [Comparative efficacy and acceptability of new-generation antidepressants. Synthesis meta-analysis Cipriani].
Gaillard R
Encephale; 2009 Oct; 35(5):499-504. PubMed ID: 19853726
[TBL] [Abstract][Full Text] [Related]
3. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.
Hidalgo RB; Tupler LA; Davidson JR
J Psychopharmacol; 2007 Nov; 21(8):864-72. PubMed ID: 17984162
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis.
Slee A; Nazareth I; Bondaronek P; Liu Y; Cheng Z; Freemantle N
Lancet; 2019 Feb; 393(10173):768-777. PubMed ID: 30712879
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological treatments for adults with post-traumatic stress disorder: A network meta-analysis of comparative efficacy and acceptability.
de Moraes Costa G; Zanatta FB; Ziegelmann PK; Soares Barros AJ; Mello CF
J Psychiatr Res; 2020 Nov; 130():412-420. PubMed ID: 32891916
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
[TBL] [Abstract][Full Text] [Related]
7. Escitalopram therapy for major depression and anxiety disorders.
Baldwin DS; Reines EH; Guiton C; Weiller E
Ann Pharmacother; 2007 Oct; 41(10):1583-92. PubMed ID: 17848424
[TBL] [Abstract][Full Text] [Related]
8. A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder.
March JS; Entusah AR; Rynn M; Albano AM; Tourian KA
Biol Psychiatry; 2007 Nov; 62(10):1149-54. PubMed ID: 17553467
[TBL] [Abstract][Full Text] [Related]
9. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
[TBL] [Abstract][Full Text] [Related]
10. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies.
Mackay FJ; Dunn NR; Wilton LV; Pearce GL; Freemantle SN; Mann RD
Pharmacoepidemiol Drug Saf; 1997 Jul; 6(4):235-46. PubMed ID: 15073774
[TBL] [Abstract][Full Text] [Related]
11. Is fluvoxamine safe and effective for treating anxiety disorders in children?
Burke JM; Baker RC
J Fam Pract; 2001 Aug; 50(8):719. PubMed ID: 11509170
[No Abstract] [Full Text] [Related]
12. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.
Cipriani A; Furukawa TA; Salanti G; Geddes JR; Higgins JP; Churchill R; Watanabe N; Nakagawa A; Omori IM; McGuire H; Tansella M; Barbui C
Lancet; 2009 Feb; 373(9665):746-58. PubMed ID: 19185342
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on fluvoxamine in anxiety disorders in children and adolescents.
Cheer SM; Figgitt DP
CNS Drugs; 2002; 16(2):139-44. PubMed ID: 11825104
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and acceptability of antidepressants and benzodiazepines for the treatment of panic disorder: A systematic review and network meta-analysis.
Du Y; Du B; Diao Y; Yin Z; Li J; Shu Y; Zhang Z; Chen L
Asian J Psychiatr; 2021 Jun; 60():102664. PubMed ID: 33965693
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis.
Williams T; McCaul M; Schwarzer G; Cipriani A; Stein DJ; Ipser J
Acta Neuropsychiatr; 2020 Aug; 32(4):169-176. PubMed ID: 32039743
[TBL] [Abstract][Full Text] [Related]
16. Medicinal herbs for the treatment of anxiety: A systematic review and network meta-analysis.
Zhang W; Yan Y; Wu Y; Yang H; Zhu P; Yan F; Zhao R; Tian P; Wang T; Fan Q; Su Z
Pharmacol Res; 2022 May; 179():106204. PubMed ID: 35378276
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of second-generation antidepressants in social anxiety disorder.
Hansen RA; Gaynes BN; Gartlehner G; Moore CG; Tiwari R; Lohr KN
Int Clin Psychopharmacol; 2008 May; 23(3):170-9. PubMed ID: 18408531
[TBL] [Abstract][Full Text] [Related]
18. Clinically relevant drug interactions in anxiety disorders.
Muscatello MR; Spina E; Bandelow B; Baldwin DS
Hum Psychopharmacol; 2012 May; 27(3):239-53. PubMed ID: 22311403
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis.
He H; Xiang Y; Gao F; Bai L; Gao F; Fan Y; Lyu J; Ma X
J Psychiatr Res; 2019 Nov; 118():21-30. PubMed ID: 31473564
[TBL] [Abstract][Full Text] [Related]
20. Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study.
Trkulja V; Kodvanj I
Eur J Clin Pharmacol; 2023 May; 79(5):643-655. PubMed ID: 36961578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
